Aligos Therapeutics, Inc.
ALGS
$7.55
-$0.82-9.80%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 223.59% | -194.53% | -6.75% | 126.93% | -51.88% |
| Total Depreciation and Amortization | -31.21% | -13.42% | -2.06% | -20.68% | -66.59% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -448.29% | 1,235.56% | -48.14% | -877.97% | 410.13% |
| Change in Net Operating Assets | 30.20% | -33.11% | 48.69% | 539.35% | -49.58% |
| Cash from Operations | 8.08% | 18.78% | 1.16% | -43.16% | -1.60% |
| Capital Expenditure | 37.68% | -300.00% | -116.67% | -200.00% | -885.71% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 50.30% | -- | 104,140.00% | 60.06% | -542.87% |
| Cash from Investing | 50.29% | 285,414.29% | 115,633.33% | 59.95% | -543.37% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -975.00% | 76.19% | 65.96% | 20.83% |
| Issuance of Common Stock | -- | -99.20% | -- | -35.57% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 535,584.21% | -99.89% | 80.95% | -32.13% | -1,800.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 133.00% | -97.45% | 52.34% | 76.08% | -4,551.65% |